For the roughly 30% of KRAS-mutant lung cancer patients who develop brain metastases, the blood-brain barrier is not merely a structural inconvenience — it is a pharmacological wall that can neutralize an otherwise effective drug. Understanding precisely which molecular gatekeepers control a therapy's access to the brain is therefore clinically critical, and new mechanistic data on daraxonrasib sharpen that picture considerably.
Daraxonrasib (RMC-6236) is an oral pan-RAS molecular glue — the first of its kind designed to lock all major RAS isoforms into an inactive conformation — currently in Phase III trials for non-small cell lung cancer, pancreatic ductal adenocarcinoma, and colorectal cancer. Preclinical pharmacokinetic work using transporter- and enzyme-deficient mouse models reveals that the efflux pump ABCB1 (P-glycoprotein) is a primary gatekeeper at the blood-brain barrier. When wild-type mice received the dual ABCB1/ABCG2 inhibitor elacridar alongside oral daraxonrasib, brain drug concentrations increased approximately 20-fold — a strikingly large magnitude. Separate experiments in OATP1A/1B-deficient mice showed significantly elevated plasma exposure, implicating hepatic uptake transporters in systemic clearance. In CYP3A4-humanized mice, plasma exposure dropped more than threefold compared to controls lacking murine Cyp3a, underscoring that human CYP3A4 substantially accelerates daraxonrasib metabolism.
This dataset is more than a pharmacokinetic footnote. The 20-fold brain penetration gain with ABCB1 inhibition raises a genuine clinical question: could co-administration of a CNS-penetrant ABCB1 inhibitor expand intracranial efficacy without dose-escalation toxicity? That strategy has historically stumbled on non-selective transporter inhibitors, but newer, selective P-gp inhibitors are in development. The CYP3A4 interaction also has immediate practical relevance, as many cancer patients take azole antifungals or other CYP3A modulators. These findings are preclinical and mouse models imperfectly recapitulate human BBB architecture, so the magnitude of the brain penetration effect in patients remains uncertain. Nonetheless, this mechanistic map provides a rational framework for daraxonrasib combination strategies and drug-interaction monitoring as the Phase III program advances.